公开(公告)号：US20240342248A1

公开(公告)日：2024-10-17

申请号：US18412278

申请日：2024-01-12

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： David Schwartzman ,  Sanjeev G. Shroff ,  Guy Salama ,  Charles McTiernan

IPC分类号： A61K38/22

CPC分类号： A61K38/2221

摘要： The present invention includes methods, systems, uses, and means for the delivery of one or more anti-fibrotic agents into the pericardial space for the treatment and prevention of heart failure (HF).

公开(公告)号：US20240342247A1

公开(公告)日：2024-10-17

申请号：US18577369

申请日：2022-07-08

申请人： GILA THERAPEUTICS, INC.

发明人： Thomas VASICEK

IPC分类号： A61K38/22 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28

CPC分类号： A61K38/22 ,  A61K38/2264 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28

摘要： The invention provides compositions and methods for inducing activating a neural receptor. The compositions include a metabolic hormone, which can be used to provide treatment for an addiction or mood disorder in a subject.

公开(公告)号：US20240335513A1

公开(公告)日：2024-10-10

申请号：US18707536

申请日：2023-05-30

申请人： Zealand Pharma A/S

发明人： Joakim LUNDQVIST

IPC分类号： A61K38/22 ,  A61K47/18

CPC分类号： A61K38/22 ,  A61K47/18

摘要： The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid formulations of amylin analogues.

公开(公告)号：US20240316153A1

公开(公告)日：2024-09-26

申请号：US18407324

申请日：2024-01-08

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Harald Rau ,  Ulrich Hersel ,  Felix Cleemann ,  Kennett Sprogøe

IPC分类号： A61K38/22 ,  A61K31/4015 ,  A61K47/18 ,  A61K47/20 ,  A61K47/60 ,  A61P19/08 ,  C07K14/58

CPC分类号： A61K38/2242 ,  A61K31/4015 ,  A61K47/183 ,  A61K47/20 ,  A61K47/60 ,  A61P19/08 ,  C07K14/58

摘要： The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.

公开(公告)号：US12083182B2

公开(公告)日：2024-09-10

申请号：US17538971

申请日：2021-11-30

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Kennett Sprogøe ,  Harald Rau ,  Ulrich Hersel ,  Felix Cleemann

IPC分类号： A61K38/00 ,  A61K38/22 ,  A61K47/60 ,  A61P43/00

CPC分类号： A61K47/60 ,  A61K38/22 ,  A61P43/00

摘要： The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

公开(公告)号：US12076373B2

公开(公告)日：2024-09-03

申请号：US16724400

申请日：2019-12-23

申请人： Entera Bio Ltd.

发明人： Gregory Burshtein ,  Ariel Rothner ,  Phillip M. Schwartz ,  Hillel Galitzer

IPC分类号： A61K38/29 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K31/05 ,  A61K31/166 ,  A61K31/19 ,  A61K31/195 ,  A61K31/20 ,  A61K38/22 ,  A61K38/55 ,  A61K47/12 ,  A61P5/18 ,  A61P19/10 ,  A61K45/06

CPC分类号： A61K38/29 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/28 ,  A61K9/2886 ,  A61K31/05 ,  A61K31/166 ,  A61K31/19 ,  A61K31/20 ,  A61K38/22 ,  A61K38/55 ,  A61K47/12 ,  A61P5/18 ,  A61P19/10 ,  A61K45/06 ,  A61K2300/00 ,  A61K38/55 ,  A61K2300/00 ,  A61K38/29 ,  A61K2300/00

摘要： A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.

公开(公告)号：US20240277813A1

公开(公告)日：2024-08-22

申请号：US18565984

申请日：2022-06-10

申请人： ANTAG THERAPEUTICS APS

发明人： Alexander HOVARD SPARRE-ULRICH ,  Mette Marie ROSENKILDE

IPC分类号： A61K38/22 ,  A61K9/00 ,  A61K38/26 ,  A61P3/04 ,  A61P3/06 ,  A61P5/50 ,  C07K14/645

CPC分类号： A61K38/2235 ,  A61K9/0019 ,  A61K38/26 ,  A61P3/04 ,  A61P3/06 ,  A61P5/50 ,  C07K14/645

摘要： The present invention relates to a glucose-dependent insulinotropic peptide (GIP) receptor (GIPR) antagonist GIP peptide in combination with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as a GLP-1 peptide, for use in the treatment of obesity and obesity-related disorders, as well as GIPR antagonist GIP peptides for treating a subset of obesity-related disorders.

公开(公告)号：US20240269134A1

公开(公告)日：2024-08-15

申请号：US18621976

申请日：2024-03-29

申请人： Tenax Therapeutics, Inc.

发明人： Stuart Rich ,  Douglas Randall ,  Douglas Hay

IPC分类号： A61K31/50 ,  A61K9/00 ,  A61K31/216 ,  A61K31/41 ,  A61K31/495 ,  A61K31/502 ,  A61K31/55 ,  A61K31/7048 ,  A61K38/22 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/40 ,  A61P9/04 ,  A61P9/12

CPC分类号： A61K31/50 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/41 ,  A61K31/495 ,  A61K31/502 ,  A61K31/55 ,  A61K31/7048 ,  A61K38/2221 ,  A61K38/2242 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/40 ,  A61P9/04 ,  A61P9/12

摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

公开(公告)号：US20240226238A1

公开(公告)日：2024-07-11

申请号：US18396828

申请日：2023-12-27

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Philippe VALET ,  Cedric Dray ,  Vincent Minville ,  Bernard Frances ,  Francois Labaste ,  Claire Vinel

IPC分类号： A61K38/22 ,  A61K31/015 ,  A61K31/02 ,  A61K31/08 ,  A61K33/00 ,  A61P23/00 ,  A61P25/28

CPC分类号： A61K38/22 ,  A61K31/015 ,  A61K31/02 ,  A61K31/08 ,  A61K33/00 ,  A61P23/00 ,  A61P25/28

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.

公开(公告)号：US20240209054A1

公开(公告)日：2024-06-27

申请号：US18371680

申请日：2023-09-22

申请人： Zealand Pharma A/S

发明人： Anne Pernille Tofteng SHELTON ,  Pia NØRREGAARD ,  Maria Alexandrovna DERYABINA ,  Bjarne Due LARSEN ,  Jacob Ulrik FOG

IPC分类号： C07K14/575 ,  A61K38/00 ,  A61K38/22 ,  A61K45/06

CPC分类号： C07K14/575 ,  A61K38/22 ,  A61K45/06 ,  A61K38/00

摘要： The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.